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Abstract
The extreme pH and protease-rich environment of the upper gastrointestinal tract is a major obstacle facing orally-
administered protein therapeutics, including antibodies. Through protein engineering, several Clostridium difficile toxin A-
specific heavy chain antibody variable domains (VHHs) were expressed with an additional disulfide bond by introducing Ala/
Gly54Cys and Ile78Cys mutations. Mutant antibodies were compared to their wild-type counterparts with respect to
expression yield, non-aggregation status, affinity for toxin A, circular dichroism (CD) structural signatures, thermal stability,
protease resistance, and toxin A-neutralizing capacity. The mutant VHHs were found to be well expressed, although with
lower yields compared to wild-type counterparts, were non-aggregating monomers, retained low nM affinity for toxin A,
albeit the majority showed somewhat reduced affinity compared to wild-type counterparts, and were capable of in vitro
toxin A neutralization in cell-based assays. Far-UV and near-UV CD spectroscopy consistently showed shifts in peak intensity
and selective peak minima for wild-type and mutant VHH pairs; however, the overall CD profile remained very similar. A
significant increase in the thermal unfolding midpoint temperature was observed for all mutants at both neutral and acidic
pH. Digestion of the VHHs with the major gastrointestinal proteases, at biologically relevant concentrations, revealed a
significant increase in pepsin resistance for all mutants and an increase in chymotrypsin resistance for the majority of
mutants. Mutant VHH trypsin resistance was similar to that of wild-type VHHs, although the trypsin resistance of one VHH
mutant was significantly reduced. Therefore, the introduction of a second disulfide bond in the hydrophobic core not only
increases VHH thermal stability at neutral pH, as previously shown, but also represents a generic strategy to increase VHH
stability at low pH and impart protease resistance, with only minor perturbations in target binding affinities. These are all
desirable characteristics for the design of protein-based oral therapeutics.
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Introduction
The gastrointestinal (GI) tract is the site of numerous microbial
infections caused by a range of pathogens, including: Helicobacter
pylori, Salmonella Typhi, Vibrio cholerae, Escherichia coli, Campylobacter
jejuni, and C. difficile. The current approach for treating most of
these infections involves administration of antibiotics, which places
selection pressure on the organism, can lead to antibiotic
resistance, and suppresses or eliminates beneficial commensal
microbes. Disease-causing pathogens of the GI tract rely on a
myriad of virulence factors for colonization, adherence, motility,
cellular entry, and pathogenesis. These include, but are not limited
to: surface-layer proteins, adhesins, invasins, flagella, high-
molecular weight toxins, and quorum sensing molecules. Inhibi-
tion of bacterial virulence factors that are essential for disease
pathogenesis therefore represents a novel, non-antibiotic based
strategy to treat infectious diseases, while reducing the risk of
microbial resistance and maintaining commensal gut populations
[1,2,3].
Several approaches are being explored for antivirulence
microbial therapy. Inhibition of E. coli pilus assembly [4], Bacillus
anthracis lethal factor [5,6], Type III secretion systems [7,8],
Staphylococcus aureus quorum sensing pathways [9], cholera toxin
[10] and C. difficile toxins A and B [11,12], with small molecules
and peptides, are examples currently under development. One of
the most pursued antivirulence strategies is targeting bacterial
toxins with antibodies. Neutralizing antibodies against anthrax
[13], shiga toxin [14], cholera toxin [15], botulinum toxin [16]
and C. difficile toxins [17,18,19,20,21] have all been successfully
isolated and a number of clinical trials involving antibodies to
bacterial targets are underway [22]. For human pathogens that
secrete toxins into the GI lumen before cellular entry, such as C.
difficile [23], it may be advantageous to neutralize the toxins within
the GI tract. Several studies indicate that oral administration of
immunoglobulins (i.e., bovine Ig, human IgA, chicken IgY) may be
successful at controlling various GI pathogens, including C. difficile
[21,24], rotavirus [25], shigella [26], and enterotoxigenic E. coli in
humans [27] and neonatal pigs [28]. However, there are major
limitations facing orally administered immunotherapeutics, in-
cluding the susceptibility of antibodies to proteolytic degradation,
instability at low pH, high dosing requirements and cost [29].
Recombinant antibody fragments, such as single-domain
antibodies (sdAbs) [30,31] isolated from conventional IgGs (i.e.,
VHs, VLs), from the heavy-chain IgG of Camelidae species (i.e.,
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agents to explore for oral immunotherapy [32] because of their
small size (12 kDa–15 kDa), high affinity, high protease and
thermal stability, high expression, amenability to library selection
under denaturing conditions for isolating superstable species and
ease of genetic manipulation. Despite possessing relatively high
intrinsic protease and pH stability, a limited number of studies
have shown that, when administered orally, sdAbs are readily
degraded in the low pH pepsin-rich environment of the stomach
and by digestive enzymes in the duodenum [33,34,35]. Several
engineering and selection-based approaches have been undertaken
to improve the thermal stability and protease resistance of sdAbs
and other recombinant antibody fragments (i.e., scFvs and Fabs).
Engineered disulfide bonds [36,37,38,39] and other stabilizing
mutations [40] have increased the thermal stability of various
recombinant fragments. Library selection of antibodies in the
presence of proteases, denaturants, extreme pH, and elevated
temperatures has lead to the isolation of antibody fragments with
favorable characteristics such as improved thermal and chemical
stability, increased protease resistance, and resistance to aggrega-
tion [41,42,43,44,45,46,47,48]. Random mutagenesis approaches
have been used to increase the proteolytic stability of VHHs [49].
There has been no universal strategy to increase recombinant
antibody thermal and protease stability simultaneously.
In this work, we hypothesized the addition of a non-canonical
disulfide bond into the hydrophobic core of llama VHHs between
framework region 2 (FR2) and FR3 would not only increase
thermal stability at neutral pH, as previously reported [37,38,50],
but would also impart resistance to proteolytic degradation and
increase antibody stability at low pH. To test this hypothesis, we
introduced two cysteine residues into a panel of VHHs which
neutralize C. difficile toxin A (TcdA) [20]. Then, the mutant VHHs
were compared to the wild-type VHH counterparts with respect to
expression yield, tendency for aggregation, antigen binding
affinity, CD structural signatures, thermal stability at neutral and
acidic pH, susceptibility to GI proteases, and toxin-neutralization
capacity.
Methods
Chemicals, Reagents, and Cell Lines
All chemicals used in this study were of analytical grade supplied
by various companies. Oligonucleotides were synthesized by
Operon (Huntsville, AL). The vectors pSJF2H [51] or pMED2
(a modified version of pSJF2H containing SfiI cloning sites) were
used for all VHH expression in E. coli cells (strain TG1) supplied by
Stratagene (La Jolla, CA).
Cloning, Expression, and Purification of VHH Mutants
The nomenclature used throughout this work to distinguish
between wild-type and mutant VHHs is exemplified as follows:
‘‘A4.2’’ denotes a wild-type VHH, ‘‘A4.2m’’ denotes a mutant
VHH. To construct mutant VHHs with a second disulfide bond,
splice-overlap extension-polymerase chain reaction (SOE-PCR)
[52] was performed using 4 primers for each VHH (Table S1) and
two rounds of PCR essentially as described [53]. Ala or Gly and Ile
codons at positions 54 and 78 (IMGT numbering system; http://
imgt.cines.fr/), respectively, were changed to Cys codons through
primer-forced mutation. In the first PCR, two mutagenized
overlapping sub-fragments were generated for each VHH. The
primer pairs used for each VHH were as follows: A4.2m (BbsI-
VHH and A4.2mR-Cys, A4.2mF-Cys and BamHI-VHH); A5.1m
(BbsI-VHH and A5.1mRCys, A4.2mFCys and BamHI-VHH);
A19.2m (BbsI-VHH and A19.2mR-Cys, A19.2mF-Cys and
BamHI-VHH); A20.1m (A20.1mSfiI-F and A20.1mR-Cys,
A20.1mF-Cys and A20.1mSfiI-R); A24.1m (A20.1mSfiI-F and
A24.1mR-Cys, A24.1mF-Cys and A20.1mSfiI-R); A26.8m (BbsI-
VHH and A26.8mR-Cys, A26.8mF-Cys and BamHI-VHH). Each
sub-fragment was gel purified and spliced with its partner
fragment in a second PCR. Briefly, 160 ng of each sub-fragment
were added to a 50 mL PCR mixture containing Pfu DNA
polymerase, dNTPs and reaction buffer. The reaction was placed
in a thermal cycler and the two fragments were spliced together
using a program consisting of a preheating step at 94uC for 5 min
and 10 cycles of 94uC for 30 s, 55uC for 30 s, and 72uC for 1 min.
To amplify the spliced products, the reaction was heated to 94uC
for 3 min, 5 pmol (0.5 mL) of each primer pair was added (BbsI-
VHH and BamHI-VHH for A4.2m, A5.1m, A19.2m, and
A26.8m; A20.1mSfiI-F and A20.1mSfiI-R for A20.1m and
A24.1m), and 35 PCR cycles were performed exactly as described
above. The resulting fragments were gel purified, digested with
BbsI and BamHI (A4.2m, A5.1m, A19.2m, and A26.8) or SfiI
(A20.1m and A24.1m) restriction enzymes, ligated into similarly
digested expression vectors (pSJF2H or pMED2), and transformed
into TG1 E. coli for VHH expression. Positive colonies were
identified by colony-PCR and DNA sequencing, using the M13RP
and M13FP primers (Table S1).
Mutant VHHs were expressed in the same vector as wild-type
VHHs [20]. Expression and purification of wild-type and mutant
VHHs were performed as described [20], followed by dialysis into
phosphate-buffered saline pH 7.3 (PBS), into distilled, deionized
water (ddH2O) for mass spectrometry (MS) analysis, or into
10 mM sodium phosphate buffer pH 7.3 for CD experiments.
MS Analysis
Proteolytic peptide fragments of mutant VHHs were created by
digestion with cyanogen bromide (CNBr) and trypsin. Briefly,
100 mL reactions containing 50 mg of mutant VHH (diluted in
PBS), 10 mL of 1 M HCl and 40 mL of CNBr (10 mg/mL stock
prepared in 1 M HCl) were digested for 14 h at ambient
temperature in the dark. The next day, 100 mL of 1 M Tris-
HCl, pH 8.6, and 60 mL of trypsin (100 mg/mL stock; sequencing
grade, Roche, Mississauga, ON, Canada) were added directly to
the CNBr reaction mixture and incubated for 2 h at 37uC.
Samples were then analyzed by non-reducing SDS-PAGE to
ensure digestion prior to MS analysis. Nano-flow reversed-phase
HPLC MS (nanoRPLC-ESI-MS) with data dependent analysis
(DDA) was performed to confirm disulfide bond formation in the
mutant VHHs. An aliquot of the CNBr/trypsin digested VHHs
was re-suspended in 0.1% formic acid (aq) and analyzed by
nanoRPLC-ESI-MS using a nanoAcquity UPLC system coupled
to a Q-TOF Ultima
TM hybrid quadrupole/TOF mass spectrom-
eter (Waters). The peptides were first loaded onto a 180 mm I.D.
620 mm 5 mm SymmetryHC18 trap (Waters), then eluted to a
100 mm I.D.610 cm 1.7 mm BEH130C18 column (Waters) using
a linear gradient from 0% to 36% solvent B (acetonitrile + 0.1%
formic acid) in 36 min, 36%–90% solvent B for 2 min. Solvent A
was 0.1% formic acid in water. The peptide MS
2 spectra were
searched against mutant VHH protein sequences using the
Mascot
TM database searching algorithm (Matrix Science, London,
UK). The MS
2 spectra of the disulfide-linked peptides were
deconvoluted using the MaxEnt 3 program (Waters) for de novo
sequencing to determine the exact disulfide-linked positions.
Size Exclusion Chromatography and Affinity
Measurements
Mutant VHHs were passed over a Superdex
TM 75 (GE
Healthcare, Baie-d’Urfe ´, QC, Canada) size exclusion chromatog-
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state. Briefly, VHHs were applied at concentrations ranging from
0.75–1 mg/mL (>45–60 mM) with a flow rate of 0.5 mL/min in a
mobile phase that consisted of HBS-EP running buffer (10 mM
HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, and 0.005% (v/v)
P20 surfactant). The collected fractions from the Superdex
TM 75
column were then used directly for surface plasmon resonance
(SPR) analysis. All kinetic rate and equilibrium constants were
determined as described [20] using a Biacore 3000 instrument (GE
Healthcare) and 10,287 resonance units (RUs) of immobilized
TcdA. In addition, the dissociation rate constants (koffs) of mutant
VHHs before and after digestion with pepsin were compared by
SPR (see below).
CD Spectroscopy
Wild-type and mutant VHHs were analyzed by CD spectroscopy
usingaJascoJ-815spectropolarimeter(Jasco,Easton,MD)atpH 7.3
(10 mM sodium phosphate buffer) and at pH 2.0 (10 mM sodium
phosphate buffer+50 mM HCl). For all CD experiments performed
at pH 2.0, proteins were equilibrated in the above buffer for a
minimum of 2 h before scanning. The 50 mM Cl
2 concentration
did contribute to a minor amount of light scatter at wavelengths less
than 200 nm.Forfar-UVCDsecondarystructurescansand thermal
unfolding experimentsa5 mmcuvette containing1.5 mLofVHHa t
50 mg/mL (3.2 mM; A280>0.1) was used. VHH concentrations of up
to 10 mM were initially tested, but signal intensities, expressed in
molar ellipticity, were identical to that of 3.2 mMV HH concentra-
tions and this concentration also avoided generating compromising
signals from protein aggregates formed at high temperatures in
thermal unfolding experiments. In these experiments, 4 accumula-
tions were collected for each sample between 190 nm–250 nm with
a 1 mm bandwidth, 20 nm/min scan speed and 0.5 nm data pitch.
Raw ellipticity data, given in millidegrees (mdeg), was smoothed
using the Jasco software, exported, and converted to molar ellipticity,
[h]. To convert from mdeg to molar ellipticity([h])indeg cm
2/dmol,
Equation 1 [54] was used,
h ½  ~ mdeg|MRW ðÞ 7 pathlength| VHH ½  ðÞ ð 1Þ
where the mean residue weight, MRW=(molecular weight of the
antibody in Da/number of backbone amino acids), pathlength=cell
pathlength in mm, and [VHH]=concentration of VHHi nm g / m L .
Thermal unfolding was followed at 215 nm with CD measurements
taken every 2uCf r o m3 0 uCt o9 6 uC with a temperature increase of
1uC/min. It should be noted that 0.5uCa n d1 uC temperature
interval measurements, on a select test VHH, gave nearly identical
Tmvaluesto2uCintervals.Molarellipticity([h])wasusedtocalculate
thefractionofproteinfolded(FF),which isshown inEquation2[55],
FF~ h ½  { hU ½  ðÞ 7 hF ½  { hU ½  ðÞ ð 2Þ
where [hF]a n d[ hU] is the molar ellipticity of the folded (30uC) and
unfolded (96uC) states, respectively. The thermal unfolding
midpoint temperature (Tm) was obtained by plotting FF against
temperature (T) and fitting with a sigmoidal Boltzmann function in
GraphPad Prism(GraphPadSoftware, LaJolla,CA).We assumed a
temperature of 30uC represented a fully folded VHH (FF=1.0) and
a temperature of 96uC represented a fully unfolded VHH (FF=0).
In the case of some VHHs with a limited number of lower baseline
data points, our Tm values are minimum estimates. We followed
unfolding at 215 nm because of a large difference in ellipticity
between folded and unfolded states at this wavelength and because
of very low light scattering in samples measured at neutral and
acidic pH. A single Tm replicate for each VHH was collected
because of the very small standard error in CD-determined Tm
values. For example, a number of previous VHH Tm replicates in
our lab, using identical conditions, produced a standard error
ranging from 60.03%–0.63% with an average error of 60.33%.
To compare the tertiary structures of wild-type and mutant
VHHs at neutral and acidic pH, near-UV CD experiments were
performed in the range of 250 nm–340 nm using the conditions
described above with the exception of a 10 mm cuvette containing
2 mL of protein at 250 mg/mL. In all cases, the ellipticity of buffer
blanks were subtracted from experimental values and the reported
data is the average of two independent experiments with 4 data
accumulations in each.
Protease Digestion Assays
The sensitivity of wild-type and mutant VHHs to the three major
GI proteases pepsin, trypsin, and chymotrypsin was explored. All
reactions were performed in 20 mL volumes with 4.8 mgo fV HH
diluted in PBS. For pepsin digestions, reactions contained 17 mLo f
VHH, 2 mL of porcine stomach pepsin (460 U/mg; Sigma,
Mississauga, ON, Canada), and 1 mL of 1 M HCl (final pH: 2.0).
Final pepsin concentrations in each reaction ranged from 0.1 mg/
mL to 100 mg/mL. Digestions were incubated at 37uC for 1 h and
neutralized with1 mL of 1 M NaOH. For trypsin and chymotrypsin
digestions, reactions contained 18 mLo fV HH (diluted in PBS
supplemented with 10 mM CaCl2)a n d2mL of either trypsin or
chymotrypsin (sequencing grade, Roche). Final trypsin/chymotryp-
sin concentrations ranged from 0.1 mg/mL to 100 mg/mL.
Digestions were incubated at 37uC for 1 h and neutralized with
1 mL of protease inhibitor cocktail (Sigma). All neutralized VHH-
protease reactions and controls (VHHs with no protease) were
separated by SDS-PAGE, stained with Coomassie and photo-
graphed using an AlphaImager3400 (Alpha Innotech Corporation,
San Leandro, CA). To determine the percent of VHH retained after
protease digestions, densitometry analysis was performed using the
AlphaEaseFc software package (Version 7.0.1, Alpha Innotech
Corporation) on control and digested VHHs. A total of three
independent digestion reactions were performed on all of the VHHs
at each protease concentration and replicate digestions were run on
separate SDS-PAGE gels. Digestions at the highest protease
concentration (100 mg/mL) that were not analyzed by SDS-PAGE
were buffer exchanged into ddH2O using Millipore Biomax 5K
MWCO spin columns (Millipore, Billerica, MA) and subjected to
MS analysis to identify the cleavage products, or analyzed by SPR
for TcdA binding activity.
Toxin Neutralization Assay
In vitro TcdA neutralization assays were performed essentially as
described [20]. Human lung fibroblast cell rounding was reported
24 h post addition of TcdA (100 ng/mL), TcdA+wild-type VHH
(1000 nM) or TcdA+mutant VHH (1000 nM). Specifically, VHHs
were added as pooled mixtures of A4.2, A5.1, A20.1, and A26.8
(250 nM each, 1000 nM total) or A4.2m, A5.1m, A20.1m, and
A26.8m (250 nM each, 1000 nM total). The percentage of cell
rounding was scored visually using light microscopy and the
reported values are the average of two independent experiments in
which each VHH mixture was tested in triplicate.
Homology Modeling
The SWISS-MODEL online workspace (http://swissmodel.
expasy.org/workspace/) [56] was used to construct homology
models of A4.2 (wild-type) and A4.2m (mutant) VHHs. The 1qd0A
(PDB) VHH was used as a template [57], sharing 73.5% and
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generated using PyMOL (www.pymol.org).
Results
Expression and Purification of Mutant VHHs
Previously, a unique dromedary ‘‘VHH’’ was isolated that
possessed a naturally occurring disulfide bond between Cys54 and
Cys78 residues [58]. When incorporated into several ‘‘wild-type’’
VHHs which possessed only the conserved Cys23/Cys104 disulfide
bond, the Cys54/Cys78 disulfide bond increased VHH thermal
and chemical stabilities [37,38]. To examine the stabilizing effects
of an engineered disulfide bond on llama-derived VHHs, we
followed this strategy and chose to introduce two cysteine residues
into the hydrophobic core of six C. difficile TcdA-specific VHHs
[20] by incorporating Ala/Gly54Cys and Ile78Cys point muta-
tions (Fig. 1A, Fig. S1), creating VHHs with two disulfide bonds.
Soluble VHHs were extracted from the periplasm of TG1 E. coli
and purified by immobilized-metal affinity chromatography
(IMAC) with purified yields ranging from 3–12 mg/L of bacterial
culture. Non-reducing SDS-PAGE and Western blot analysis of
the purified products revealed the mutant VHHs were of high
purity and did not form interdomain disulfide bonds (Fig. 1B). On
non-reducing SDS-PAGE gels, mutant VHHs consistently ran
slower than their corresponding wild-type VHHs (Fig. 1C).
MS Analysis
The molecular weights of all mutant VHHs were determined,
but were not accurate enough to confirm the formation of the
engineered disulfide bond. To precisely confirm the presence of
Figure 1. Design, purification, and size exclusion chromatography profiles of disulfide bond mutant VHHs. (A) Representative
homology models of A4.2 and A4.2m were built on the PDB template 1qd0A VHH [57], sharing 73.5% and 71.8% homology, respectively. Disulfide
bonds are shown as colored spheres in the hydrophobic core of the VHH domains. (B) Non-reducing (NR) SDS-PAGE analysis and Western blot (WB)
probed with an anti-His6 IgG on IMAC-purified mutant VHHs. M: molecular weight marker in kDa. (C) Representative SDS-PAGE analysis showing
mutant VHHs run slower than the corresponding wild-type VHHs under non-reducing conditions. (D, E) Size exclusion chromatography (SEC) analysis
of wild-type and mutant VHHs revealed similar size exclusion profiles, indicating the second disulfide bond does not promote the formation of
interdomain disulfide-bonds or multimeric mutant VHHs. The elution volumes (Ves) of SEC molecular weight standards are shown with arrows and are
aligned relative to the A4.2 and A4.2m chromatograms. a: ovalbumin (MW=43.0 kDa, Ve=8.90 mL); b: carbonic anhydrase (MW=30.0 kDa,
Ve=9.71 mL); c: trypsin inhibitor (MW=20.1 kDa, Ve=11.06 mL); d: a-lactalbumin (MW=14.4 kDa, Ve=11.97 mL); e: vitamin B (MW=1.3 kDa,
Ve=18.7 mL). The equation of the line of a standard curve generated from these standards was LOG10MW~{0:1539Vez2:9949 (r2~0:9995).
From this equation the VHH apparent MWs ranged from 9.8 kDa–13.6 kDa, indicating monomeric VHHs.
doi:10.1371/journal.pone.0028218.g001
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CNBr and trypsin (Fig. 2A, B) and their digests subjected to MS
2
analysis. The identification coverage of the mutant VHHs from the
analysis of their CNBr/trypsin digests using nanoRPLC-ESI-MS
with DDA was more than 30%. The disulfide-linked peptide ions
appeared prominent in the survey scan of the DDA experiment
when the proteins were digested with a combination of CNBr and
trypsin. Peptide fragments linked by the engineered Cys
54–Cys
78
disulfide bond (shown in blue text in Fig. S1) were positively
identified for all mutant VHHs by manual de-novo sequencing
(Table 1). For example, the protein sequence coverage of A5.1m
was 43% and a prominent ion at m/z 526.25 (3+) was sequenced as
a disulfide-linked peptide EFVCVITR (P1) and FTCSR (P2) as
shown (Fig. 2C, Fig. S1, Table 1). An almost complete disulfide-
linked y fragment ion series was observed from one peptide with the
other peptide attached as a modification via a disulfide bond, which
remains intact under collision induced dissociation (CID) [59].
Size Exclusion Chromatography and Affinity
Measurements
Analysis of mutant VHHs on a Superdex
TM 75 size exclusion
chromatography column produced single, monomeric peaks
nearly identical to the profile for wild-type VHHs (Fig. 1D, E),
confirming the mutant VHHs are non-aggregating. SPR analysis
revealed the specific and high-affinity binding of 4 of 6 mutant
VHHs to TcdA (Fig. 3, Table 2). These four were also the strongest
TcdA neutralizers. Two mutants (A19.2m and A24.1m) exhibited
non-specific binding to reference cell proteins and as a result
specific interaction data could not be generated, even at antibody
concentrations as high as 3.2 mM. When compared to their wild-
type counterparts, the KDs of 3 TcdA-binding mutants were
reduced approximately 2–6 fold (Table 2), while the affinity of one
VHH was relatively unchanged (KDs of 24 nM and 20 nM for
A4.2 and A4.2m, respectively). The KD reductions were largely a
result of faster koff values and to a much lesser extent influenced by
Figure 2. Disulfide bond formation between residues Cys
54 and Cys
78 is confirmed by MS
2. (A) Schematic diagram of mutant VHH
digestion with cyanogen bromide (CNBr) and trypsin before MS
2 analysis. (B)V HHs (3 mg per lane) were subjected to SDS-PAGE analysis under non-
reducing (NR) conditions to illustrate near complete digestion with CNBr and trypsin. Untreated A5.1m was added as a control (Ctl). M: molecular
weight marker in kDa. (C) MaxEnt 3 deconvoluted CID-MS
2 spectrum of the m/z 526.25 (3+) ion of the disulfide-linked peptide EFVCVITR (P1) – FTCSR
(P2), encompassing the Cys
54–Cys
78 disulfide bond, from CNBr/trypsin digested A5.1m.
doi:10.1371/journal.pone.0028218.g002
Protease Resistant, Thermostable VHHs
PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e28218slower kon values. In general, these data suggest the Cys
54–Cys
78
disulfide bond may slightly distort the VHH structure leading to
decreases in target binding affinities and decreases in antibody
specificity.
VHH Structural and Thermal Stability Characterization
CD experiments were used to examine VHH secondary
structure, tertiary structure, and thermal stability at both neutral
and acidic pH. We first examined VHH secondary structure by
far-UV CD (Fig. 4A, Fig. S2). Although the overall shape of the
far-UV CD spectra from wild-type and mutant VHH pairs was
similar at a given pH, spectra intensity shifts were observed for all
wild-type/mutant pairs. In general, peak minima were seen at
216 nm–218 nm and at 230 nm–235 nm wavelengths but, in
almost all cases, the intensity of the peak at 216 nm–218 nm was
lower (decreased negative ellipticity) for mutant VHHs. Another
prominent feature in the far-UV CD spectra was that mutant
VHHs exhibited a near-UV shift in the peak range of 230 nm–
235 nm. Wild-type VHHs possessed peak minima around
230 nm–232 nm whereas mutants displayed peak minima in this
region around 232 nm–235 nm. Interestingly, A4.2/A4.2m,
which of all the wild-type/mutant pairs had the most similar
CD spectra at neutral pH, also had the same binding affinity for
TcdA.
We next examined VHH tertiary structures with near-UV CD
spectroscopy (Fig. 4B, Fig. S3). The CD spectra in this region
(250 nm–320 nm) come primarily from aromatic residues within
the VHH, with Phe contributing in the range of 250 nm–270 nm,
Tyr contributing in the range of 270 nm–290 nm, and Trp
contributing in the range of 280 nm–300 nm. Overall, the near-
UV spectra profiles were similar between wild-type and mutant
VHH pairs. Spectra from wild-type and mutant pairs shared nearly
identical peak wavelengths; however, between 250 nm to 295 nm,
the ellipticity of mutant VHHs was consistently more negative than
wild-type VHHs. There were also subtle differences in peaks
occurring around 297 nm, with mutant VHHs exhibiting a minor
but consistent shift to the right. Three of the four wild-type/
mutant pairs (A4.2/A4.2m, A5.1/A5.1m, and A20.1m/A20.1m)
produced predominantly negative ellipticity, whereas the A26.8/
A26.8m pair remained positive. The contributions of the second
disulfide bond cannot be ruled out as a factor which may augment
the contribution of aromatic residues to ellipticity (increasing
negatively) of the mutants.
Finally, temperature-induced unfolding experiments were
conducted in order to determine VHH Tms and Tonsetsb y
following changes in VHH ellipticity at 215 nm (Fig. 5, Fig. S4,
Table 3, Table S2). All VHHs exhibited sigmoidal melting curves,
indicative of cooperative unfolding of a protein that exists in either
a folded or unfolded state. The wild-type VHHs already have high
Tms (as high as 84.7uC) – significantly higher than those reported
for other VHHs [60]. At neutral pH, all mutant VHHs had
significantly higher thermal unfolding midpoint temperatures
(p=0.031, unpaired two-tailed t-test) than their wild-type VHH
counterparts. The Tm values of mutants ranged from 78.8uCt o
93.6uC, with one mutant, A5.1m, having a Tm 11.6uC higher than
wild-type (A5.1). The increase in mutant VHH Tms relative to
wild-type ranged from 3.7uC to 11.6uC. Overall, at neutral pH,
the mean Tm 6 SEM was 76.2uC61.8uC and 83.6uC62.3uC for
wild-type and mutant VHHs, respectively (Fig. 5B). These findings
are in agreement with previous reports that showed significant
increases in the Tms of disulfide bond engineered VHHs
[37,38,50]. In a second series of experiments, temperature-
induced unfolding was conducted at pH 2.0 by once again
following VHH ellipticity changes at 215 nm (Fig. 5, Fig. S4,
Table 3). At acidic pH a considerable reduction in Tm was
observed for both wild-type (22.1uC to 32.4uC) and mutant VHHs
(23.7uC to 31.2uC) when compared to the Tm values recorded at
pH 7.3. However, at acidic pH the Tm of all six mutants was still
significantly higher than the corresponding wild-type VHHs
(p=0.002, unpaired two-tailed t-test). In acid, the increase in
mutant VHH Tms relative to wild-type ranged from 2.1uCt o
11.6uC, which is a nearly identical spread in temperature increases
to that seen at neutral pH. Overall, at pH 2.0, the mean Tm 6
SEM was 49.3uC61.2uC and 56.6uC61.2uC for wild-type and
mutant VHHs, respectively (Fig. 5B). Interestingly, the highest Tm
gains at both pHs were seen for the four strongest neutralizers.
The Tm differences between wild-type/mutant pairs are more
significant at acidic pH than neutral pH. Taken together, these
results (Table 3; Fig. 5) suggest the Cys
54–Cys
78 disulfide bond
may stabilize the VHHs from acid-induced denaturation. Using
our thermal unfolding curves, we also identified VHH Tonset
temperatures, the temperature at which 5% of the VHH was
unfolded (Fig. 5C; Table S2). The Tonset of mutant VHHs was
significantly higher than wild-type VHHs at both neutral and
acidic pH (p=0.027 and p=0.006, respectively, unpaired two-
tailed t-test). The Tonset differences between wild-type/mutant
pairs are more significant at acidic pH than neutral pH. At
pH 7.3, the mean Tonset 6 SEM was 68.9uC61.8uC and
74.9uC61.5uC for wild-type and mutant VHHs, respectively. At
pH 2.0, the mean Tonset 6 SEM was 41.2uC61.3uC and
47.3uC61.3uC for wild-type and mutant VHHs, respectively.
Therefore, the lowest Tonset for the mutants was 45.0uC, whereas
two of the wild-type VHHs (A5.1, A20.1) already had Tonsetso f
,37uC at pH 2.0 (physiological stomach conditions).
Protease Digestion Assays
Proteins traveling through the GI tract encounter low pH and
digestive enzymes in the stomach. We therefore asked if the Cys
54–
Cys
78 disulfide bond improved VHH resistance to proteolytic
degradation. We compared the effects of the major GI proteases
pepsin, trypsin, and chymotrypsin on wild-type and mutant VHHs
through SDS-PAGE and MS analysis. Initially, protease concen-
trations of 0.1 mg/mL, 1 mg/mL, 10 mg/mL, and 100 mg/mL
were explored. When the lowest concentrations of proteases
(0.1 mg/mL and 1 mg/mL) were used in digestion reactions, wild-
type and mutants appeared similar to undigested controls on SDS-
PAGE (data not shown). Similarly, VHHs were only moderately
Table 1. Disulfide linkage determination of mutant VHHs by
MS
2 analysis.
VHH CNBr/tryptic peptides MWfor MWexp DMW
A4.2m EFVCAVSR FTCSR 1519.69 1519.70 20.01
A5.1m EFVCVITR FTCSR 1575.75 1575.76 20.01
A19.2m EFVCGISR FTCSR 1519.69 1519.64 0.05
A20.1m EFVCAGSSTGR FTCSR 1722.74 1722.84 20.10
A24.1m EFVCGISWGGGSTR FTCSR 2064.91 2064.98 20.07
A26.8m EFVCVISSTGTSTYYADSVK FTCSR 2766.25 2766.33 20.08
Mutant VHHs were digested with CNBr and trypsin and the peptides analyzed
by MS
2. The peptides containing the Cys
54–Cys
78 disulfide linkage are shown
with connecting cysteines bolded. A nearly perfect match between MWfor and
MWexp equates to the presence of the Cys
54–Cys
78 disulfide linkage. MWfor:
formula (expected) molecular weight (Da); MWexp: experimental molecular
weight (Da); DMW~MWfor{MWexp.
doi:10.1371/journal.pone.0028218.t001
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In order to see clear differences in the proteolytic susceptibility of
wild-type and mutant VHHs, all remaining digestions were
performed at protease concentrations of 100 mg/mL. SDS-PAGE
analysis of pepsin-digested wild-type and mutant VHHs showed a
reduction in VHH size from ,16 kDa (control) to either ,14 kDa,
or complete digestion to smaller fragments (Fig. 6A). The band at
,14 kDa routinely appeared in digestions with each of the
Figure 3. Mutant VHHs retain high affinity binding to TcdA. (A) SPR sensorgrams demonstrating mutant VHHs retained high affinity binding
to immobilized C. difficile TcdA. The range of VHH concentrations used in each experiment is shown. Red lines represent measured interaction data,
and black lines represent fitted curves. The kinetic and affinity constants are reported in Table 2. Binding of A19.2m and A24.1m to TcdA was non-
specific, and the kinetic and affinity constants could not be determined. (B) Rate plane plot with iso-affinity diagonals comparing wild-type (red) and
mutant VHHs (blue).
doi:10.1371/journal.pone.0028218.g003
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analysis on the ,14 kDa products revealed cleavage at various
positions within the VHH C-terminal c-Myc epitope tag. Loss of
the epitope tag corresponded to reductions of 1641.7 Da,
1754.8 Da, and 1641.7 Da for pepsin, trypsin, and chymotrypsin
digested VHHs, respectively (data not shown).
Overall, significant increases in pepsin resistance were found for
all mutant VHHs compared to their wild-type counterparts
(p=0.026, Mann-Whitney U test) (Fig. 6B; Fig. 7; Table 4). The
increase in mutant VHH pepsin resistance relative to correspond-
ing wild-type ranged from almost 4.5% to 63% (Table 4). For
example, A5.1 was completely degraded after incubation with
pepsin, while nearly 50% of A5.1m remained intact (Fig. 6A, B).
The biggest increase in pepsin resistance was found for A4.2m,
where an almost 63% increase in intact VHH structure was found
relative to A4.2. Interestingly, A4.2m also had the highest Tm and
Tonset at pH 2.0 (Table 3; Table S2), the same pH at which the
pepsin digestions were performed. Increases in mutant VHH
resistance to chymotrypsin were not as universal (Fig. 7; Fig. S5,
Table 4) but, nonetheless, 4 of 6 mutant VHHs showed increased
resistance to chymotrypsin, with significant increases found in
clones A5.1m, A24.1m, and A26.8m (p,0.05) compared to their
wild-type counterparts. No statistical differences were found
between trypsin digested wild-type and mutant VHHs (Fig. 7;
Fig. S5, Table 4), except for A4.2m, where trypsin resistance was
actually reduced from almost 36% in the wild-type VHH to almost
5% in the mutant. Both the wild-type and mutant versions of
A19.2 and A26.8 were very susceptible to trypsin degradation.
A correlation was observed between VHH pepsin resistance and
Tms at pH 2.0 (r
2=0.735, Fig. 8A). The wild-type VHHs with
Table 2. Kinetic and affinity constants of wild-type and mutant VHHs.
VHH Wild-type
a Mutant
Fold change in
KD
b
kon (M
21 s
21) koff (s
21) KD (nM) kon (M
21 s
21) koff (s
21) KD (nM)
A4.2/A4.2m 6.7610
5 1.6610
22 24 9.3610
5 1.9610
22 20 21.2
A5.1/A5.1m 1.6610
6 5.0610
23 39 . 5 610
5 1.6610
22 17 +5.7
A19.2/A19.2m 1.4610
4 3.9610
23 290 – – –
A20.1/A20.1m 8.2610
5 1.6610
23 26 . 4 610
5 5.9610
23 9.2 +4.6
A24.1/A24.1m 6.0610
4 1.6610
22 260 – – –
A26.8/A26.8m 1.4610
6 1.6610
22 12 1.0610
6 2.8610
22 28 +2.3
aData obtained from [20].
bRelative to wild-type VHH.
doi:10.1371/journal.pone.0028218.t002
Figure 4. Representative far-UV and near-UV CD spectra of wild-type and mutant VHHs at neutral and acidic pH. Far-UV CD spectra (A)
and near-UV CD spectra (B) of A4.2/A4.2m and A5.1/A5.1m at neutral and acidic pH. Far-UV scans (210 nm–260 nm) were performed at 25uCo nV HHs
(50 mg/mL) equilibrated for 2 h in 10 mM sodium phosphate buffer (pH 7.3) or 10 mM sodium phosphate buffer+50 mM HCl (pH 2.0) in a 5 mm
cuvette. Near-UV scans (250 nm–340 nm) were performed at 25uCo nV HHs (250 mg/mL) under similar conditions in a 10 mm cuvette. All spectra
represent the mean residue ellipticity from 8 data accumulations collected from 2 independent experiments. Raw data were smoothed using the
Jasco software and converted to mean residue ellipticity as described in Methods. Red lines: wild-type VHH at pH 7.3; blue lines: mutant VHH at pH 7.3;
green lines: wild-type VHH at pH 2.0; orange lines: mutant VHH at pH 2.0.
doi:10.1371/journal.pone.0028218.g004
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graph, the mutants with higher Tms occupied the high protease
resistance region of the graph. There was also a moderate
correlation between VHH pepsin resistance and Tms at pH 7.3
(r
2=0.500, data not shown). No correlation was evident between
VHH trypsin resistance and Tms at pH 7.3 or pH 2.0 (r
2=0.138
and r
2=0.138, respectively) or between VHH chymotrypsin
resistance and Tms at pH 7.3 or pH 2.0 (r
2=0.012 and
r
2=0.004, respectively). In addition, a strong correlation between
wild-type VHH pepsin resistance and wild-type VHH Tonset at
pH 2.0 was noted (r
2=0.975, Fig. 8B, Table S2). No correlation
was evident between mutant VHH pepsin resistance and mutant
VHH Tonset at pH 2.0 (r
2=0.191), presumably because mutant
VHH Tonset temperatures were much higher than the temperature
at which pepsin digestions were performed (37uC). Interestingly,
we also noted a correlation between VHH trypsin resistance and
the theoretical number of trypsin cleavage sites located within the
whole VHH( r
2=0.822) or located within the VHH CDR
(r
2=0.681) regions (Table S3, Fig. S6). No correlation was found
between VHH pepsin or chymotrypsin resistance and the
theoretical number of pepsin or chymotrypsin cleavage sites,
respectively (Fig. S6).
The ability of pepsin-treated mutants (A4.2m, A5.1m, A20.1m,
and A26.8m) to bind TcdA was evaluated by SPR. SPR analyses
confirmed the mutants (‘‘VHH2tag’’; see Fig. 6A) retained TcdA
binding as their koff values were essentially the same as those of
untreated controls (Table 2; Fig. 6C). SPR analysis on pepsin-
digested wild-type VHHs could not be performed since these
Figure 5. Mutant VHH thermal unfolding midpoint temperatures are significantly greater than those of wild-type VHHs. (A)
Representative example showing the thermal unfolding of A26.8 (WT) and A26.8m (Mut) at neutral pH (left) and acidic pH (right). VHH thermal
unfolding midpoint temperatures (Tms) were determined using CD spectroscopy by following antibody unfolding (50 mg/mL) at 215 nm in 10 mM
sodium phosphate buffer +/250 mM HCl. Raw data were converted to fraction folded, as described in Methods, and the Tm was determined by
Boltzmann sigmoidal curve fitting (r
2 ranging from 0.9965–0.9995). Tonset was determined from the same curve and was defined as the temperature
at which 5% of the VHH was unfolded. Red lines: wild-type VHH at pH 7.3; blue lines: mutant VHH at pH 7.3; green lines: wild-type VHH at pH 2.0;
orange lines: mutant VHH at pH 2.0. (B) Summary of VHH Tms. (C) Summary of VHH Tonsets. In B and C, dots represent individual VHHs and the black
bars represent the mean Tm or Tonset, respectively. P-values were determined using the unpaired two-tailed t-test.
doi:10.1371/journal.pone.0028218.g005
Table 3. Thermal unfolding midpoint temperatures (Tm)o f
wild-type and mutant VHHs.
VHH Tm (6C) at pH 7.3 Tm (6C) at pH 2.0
Wild-type Mutant DTm Wild-type Mutant DTm
A4.2/A4.2m 84.7* 93.6* 8.9 52.3 62.4 10.1
A5.1/A5.1m 73.1 84.7* 11.6 45.6 57.2 11.6
A19.2/A19.2m 75.1 78.8 3.7 53.0 55.1 2.1
A20.1/A20.1m 72.4 79.1 6.7 46.6 55.4 8.8
A24.1/A24.1m 74.6 80.1 5.5 49.4 54.6 5.2
A26.8/A26.8m 77.2 85.3* 8.1 48.8 54.8 6.0
*Minimum estimated Tm.
doi:10.1371/journal.pone.0028218.t003
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highlight the profound impact a second disulfide bond in the
hydrophobic core has on VHH conformational stability at low pH
and resistance to proteolytic degradation by pepsin.
Toxin Neutralization Assay
Mutant VHHs retained their ability to neutralize to cytotoxic
effects of TcdA on monolayers of fibroblast cells. Comparison of
the neutralization capacity of pooled mixtures (1000 nM total) of
wild-type and mutant VHHs revealed mutants performed nearly as
well as wild-types at reducing TcdA-mediated cell rounding
(Fig. 9). Given that 3 of 4 mutants showed weaker affinity for
TcdA the reduction in neutralizing capacity relative to wild-type
VHHs was not unexpected.
Discussion
The rapid development of bacterial resistance to most major
classes of antibiotics has created a demand for novel therapeutics
in the fight against infectious diseases. One of the most pursued
non-antibiotic strategies involves targeting bacterial virulence
factors with small molecules and antibodies. For some pathogens,
inhibition of toxins and colonization factors within the GI tract
may be an effective means of disease control. Oral immunother-
apy for treating infectious diseases has had limited success due to
the instability of immunoglobulins in the extreme pH and
protease-rich environment of the GI tract. Here, through protein
engineering, we increased the protease, acid and thermal stability
of llama-derived sdAbs (VHHs) which target and neutralize C.
difficile toxin A without dramatically affecting biological function.
Our stabilization strategy involved the substitutions of two
amino acid residues at positions 54 and 78 for cysteine, allowing
for the formation of a second, non-native disulfide bond between
FR2 and FR3 in the VHH hydrophobic core. Incorporation of a
disulfide bond at these positions has been previously reported in
camelid VHHs [37,38,50] and was found to increase VHH
chemical and thermal stability. We hypothesized that the
additional disulfide bond may also enhance VHH resistance to
proteases, especially in denaturing acidic conditions.
Figure 6. Mutant VHHs are resistant to pepsin degradation. (A)
Representative SDS-PAGE analysis showing the separation of A5.1 and
A5.1m VHHs after digestion with various concentrations of pepsin
(increasing from left to right: 1 mg/mL, 10 mg/mL and 100 mg/mL) at
pH 2.0 and 37uC for 1 h. Control VHHs (Ctl) were incubated under the
same conditions without pepsin. Three micrograms of protein was
loaded per lane. Bands appearing ,2 kDa below the full-length VHH
(‘‘VHH+tag’’) were identified by MS (data not shown) as VHHs cleaved
within the C-terminal c-Myc tag (‘‘VHH2tag’’), as shown before with
protease-digested human VHs [61]. (B) Summary of VHH resistance
profiles to 100 mg/mL pepsin treatment. Resistance values were
obtained by densitometric measurements of pepsin-treated VHHs
relative to controls (as in Fig. 6A). Error bars represent the SEM
obtained from 3 independent digestions for each VHH. (C) SPR analysis
(bottom) on mutant VHHs digested with pepsin (100 mg/mL, 1 h, 37uC).
The pepsin-treated VHHs retained their ability to bind surface-
immobilized TcdA. SDS-PAGE (top) showing untreated (lanes 1, 3, 5,
7) and pepsin-digested (lanes 2, 4, 6, 8) VHHs used for SPR. The contents
of lanes 1 thru 8 are described in the box in C. Normalized koffs for
pepsin treated VHHs were similar to the koff of untreated controls (box
and Table 2). M: molecular weight markers in kDa; WT: wild-type VHH;
Mut: mutant VHH; P: pepsin; R: reducing SDS-PAGE conditions.
doi:10.1371/journal.pone.0028218.g006
Figure 7. Summary of VHH resistance profiles to pepsin,
trypsin, and chymotrypsin. VHH resistance to the major GI proteases
was determined by proteolytic digestion (100 mg/mL protease, 37uC,
1 h) and SDS-PAGE densitometry analysis. Dots represent the mean
(n=3) protease resistance profile of each VHH relative to undigested
controls and the black bars represent the median resistance of each
group. P-values were determined using the unpaired two-tailed Mann-
Whitney U test. WT: wild-type VHH; Mut: mutant VHH; Chymo:
chymotrypsin.
doi:10.1371/journal.pone.0028218.g007
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and compared them to their wild-type counterparts containing
only the native disulfide bond between residues 23 and 104.
Mutant VHHs were well expressed in E. coli when targeted to the
periplasmic space, although with lower yields compared to wild-
type VHH counterparts, and all were non-aggregating monomers
as determined by size exclusion chromatography. To confirm
disulfide bond formation, we used a combination of proteolytic
and chemical digestion coupled with MS
2 to precisely identify
VHH peptide fragments harboring the introduced disulfide bond.
This approach is preferred over the Ellman’s assay approach for
the determination of disulfide linkage formation, as it requires less
quantities of protein and reveals the positional identity of Cys pairs
in a given disulfide bond. The latter information is important, as
there is also the possibility that the two engineered Cys residues,
besides forming the desired disulfide bond may form undesired
disulfide bonds with the two conserved Cys residues at positions 23
and 104. After confirming disulfide bond formation in our
mutants, SPR binding experiments revealed most mutant VHHs
possessed 1- to 5-fold weaker affinity constants relative to wild-
type, which is consistent with observations by others of up to 3-fold
Table 4. Protease resistance profiles of wild-type and mutant VHHs to the major GI proteases.
VHH Pepsin resistance (%) Chymotrypsin resistance (%) Trypsin resistance (%)
Wild-type Mutant Wild-type Mutant Wild-type Mutant
A4.2/A4.2m 11.0861.88 73.8767.23 13.6066.50 3.1861.10 35.7267.08 4.8060.61
A5.1/A5.1m 0.5360.15 46.6361.99 14.0363.15 27.0064.05 96.2367.09 83.3064.96
A19.2/A19.2m 30.3763.16 52.2760.32 8.3061.14 0.1860.10 0.7360.73 0.2760.27
A20.1/A20.1m 0.6860.68 5.0460.76 10.1761.85 16.1765.26 72.7764.85 82.8061.97
A24.1/A24.1m 10.4562.39 36.0261.11 22.0365.01 43.8062.08 75.0369.63 66.5063.58
A26.8/A26.8m 3.1761.24 24.5661.45 8.4061.23 40.8368.81 2.0362.03 4.1061.27
All VHH digestions were performed at 37uC for 1 h in the presence of 100 mg/mL protease. Resistance values were obtained by comparing the intensity of protease-
digested VHHs relative to untreated controls using SDS-PAGE and imaging software. See Fig. 6A as an example. Values represent the mean 6 SEM (n=3). Data were
incorporated into Fig. 6B and Fig. S5.
doi:10.1371/journal.pone.0028218.t004
Figure 8. Correlation between VHH pepsin resistance and
thermal stability at acidic pH. (A) Linear regression between VHH
pepsin resistance and VHH Tm at pH 2.0. Red and blue boxes show the
wild-type (WT) and mutant (Mut) VHHs, respectively. Linear regression
analysis gave a correlation coefficient of r
2=0.735 and a significantly
non-zero slope of the line (p=0.0004). (B) Linear regression between
wild-type VHH pepsin resistance and wild-type VHH Tonset at pH 2.0. The
Tonset is defined as the temperature at which 5% of the VHH is unfolded.
Linear regression analysis gave a correlation coefficient of r
2=0.975 and
a significantly non-zero slope of the line (p=0.0002).
doi:10.1371/journal.pone.0028218.g008
Figure 9. Mutant VHHs retain TcdA-neutralizing capacity.
Confluent monolayers of IMR-90 human lung fibroblasts were
incubated with TcdA (100 ng/mL) or TcdA+VHHs (1000 nM) for 24 h,
and the percentage of cells rounded was scored using a light
microscope from 0% to 100%. VHHs (wild-type (WT) or mutant (Mut))
were added as pooled mixtures of A4.2, A5.1, A20.1, and A26.8 (250 nM
each) or A4.2m, A5.1m, A20.1m, and A26.8m (250 nM each).
doi:10.1371/journal.pone.0028218.g009
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introduced disulfide bond [38,50]. However, for the two weak
neutralizing VHHs, A19.2m and A24.1m, the non-canonical
disulfide linkage compromised specificity.
We used CD spectroscopy to compare wild-type and mutant
VHH secondary structure, tertiary structure and thermal stability
(Tm and Tonset). Comparisons of VHH secondary and tertiary
structure with far-UV and near-UV CD spectroscopy strongly
suggested structural differences between wild-type and mutants, at
both neutral and acidic pH. For all mutants, peak intensity and
selective peak minima shifts were observed, although the overall
spectral profiles remained very similar in all wild-type/mutant
pairs. More specifically, mutants consistently showed rightward
peak shifts in the peak range of 230 nm–235 nm (far-UV CD
spectra) and around 297 nm (near-UV CD spectra) compared to
wild-type VHHs. Such patterns may be used as signatures that
could be used to quickly identify VHHs containing a properly
formed non-canonical disulfide bond, as could SDS-PAGE
motility values since, compared to wild-type VHHs, mutants
consistently moved slower in SDS-PAGE gels. Thus, the far- and
near-UV CD spectral data suggests the introduced disulfide bond
changes the structure of VHHs. This is consistent with the
observed perturbations in affinities and specificities and increased
GI protease resistance of the mutant VHHs compared to the wild-
types (see below). We used CD spectroscopy thermal denaturation
experiments to show a profound and significant increase in the
Tms and Tonsets of mutant VHHs at both neutral and acidic pH.
These mutants are more thermostable than previously reported
VHs, which were affinity selected from a VH phage display library
under stability pressure [45]. The beneficial effect of the non-
canonical disulfide linkage on Tms varies widely, with Tm increases
ranging from <4uCt o<12uC. This suggests that for the mutant
VHHs with a higher thermostability gain, the non-canonical
disulfide linkage may have been a better fit to the overall fold.
A19.2m and A24.1m showed the lowest thermostability gains and,
if it is true that this is because of an unfit disulfide linkage, it would
explain why they were transformed into non-specific binders upon
mutation. For A4.2m on the other hand, the non-canonical
disulfide linkage seems to be a natural fit, as it increased its Tm the
most (by almost 12uC) and significantly improved GI protease
resistance (with the highest increase in pepsin resistance; see below),
all without adversely affecting the KD. We also observed a
correlation between pepsin resistance and Tm, and this has
implications in terms of using heat as the selective pressure for
selecting pepsin resistant antibody fragments by in vitro evolution-
ary approaches.
Most likely, mutants (exhibiting higher Tms) also have higher
thermodynamic stability since thermodynamic stability generally
increases with Tm [62]. This has been shown to be the case for
both VH and VHH domains as well [38,45]. In the instance of
VHHs, it has been shown that the introduction of the Cys54/
Cys78 disulfide linkage used in our study into VHHs led to
increases in both Tm and thermodynamic stability. Proteins with
higher Tm are also less likely to unfold [62]. These may be the
reasons why our mutants were more resistant to acid-induced
unfolding at 37uC, supported by the higher Tonsets and pepsin
resistance of our mutant VHHs (see below). Consistent with this, in a
previous study, human VHs which were more resistant to acid-
induced aggregation, a phenomenon encouraged/initiated by
protein unfolding, had higher Tms and thermodynamic stabilities
[45]. The improved reversibility of thermal unfolding of mutant
VHHs compared to their wild-type counterparts under acidic
conditions in our work (data not shown) indicates that the
introduced disulfide linkage may also render VHHs with
aggregation resistant unfolded states [48], in addition to higher
thermodynamic stability. Hagihara et al [37] showed that the
introduction of the same Cys54/Cys78 disulfide linkage into a
VHH, in addition to increasing its Tm, led to decreases in its
enthalpy and entropy changes of unfolding. The enthalpy and
entropy measurements indicated that the stabilization effect of the
extra disulfide linkage in VHHs may be related to factors such as
loop entropy, internal interactions such as hydrogen bonding and
van der Waals interactions and hydration of the native and
unfolded states.
We also examined the resistance profiles of the disulfide bond
mutants to the major GI proteases. Mutant VHHs were universally
more resistant to pepsin and many were more resistance to
chymotrypsin when compared to their wild-type counterparts.
Protease sensitivity is a function of many variables including the
location of proteolytic sites (e.g., loops vs protein core in
antibodies), the theoretical number of proteolytic sites, and protein
compactness and thermodynamic stability [63,64]. Since each
wild-type and mutant VHH pair possessed the identical number of
theoretical protease cleavage sites, we speculate that the second
disulfide bond presents a more compact and thermodynamically
stable VHH structure, preventing pepsin and chymotrypsin from
accessing proteolytic cleavage sites. This view is consistent with the
increased Tms in mutants (an indicator of mutants’ increased
thermostability), the positive correlation between pepsin resistance
and Tm (Fig. 8), and the lack of correlation between pepsin/
chymotrypsin resistance and the number of theoretical protease
cleavage sites (Fig. S6). The pepsin resistance vs Tm/Tonset
correlation curves also point to the fact that structural compactness
and thermodynamic stability plays a more prominent role in
pepsin resistance, which is understandable given that pepsin
requires protein unfolding for efficient digestion. This benefit is not
realized for mutants against trypsin, possibly because their
cleavage sites are at hydrophilic residues (Lys or Arg) which must
be in more exposed regions of the VHH, possibly located in the
CDR regions. Further, these regions would not be protected by
stabilizing the core of the structure. The positive correlation
between VHH trypsin resistance and the number of theoretical
trypsin cleavage sites is a testament to this (Fig. S6). Harmsen et al
[49] have suggested the CDR regions of VHHs to be the most
sensitive sites to proteolysis due to their flexibility and exposed
position relative to the VHH core. Indeed, there are more
predicted trypsin-cleavage sites in the CDR regions (Table S3; Fig.
S6) of trypsin-sensitive VHHs (A4.2, A19.2 and A26.8) compared
to trypsin-resistant VHHs (A5.1, A20.1 and A24.1). This is not the
case for pepsin and chymotrypsin sensitivities (Table S3; Fig. S6).
Importantly, we also observed an increase in Tonset tempera-
tures for mutants at the physiological conditions representative of
the stomach (pH > 2.0 and 37uC) to values significantly above
37uC( Tonsets from 45uC–53uC). This suggests that the mutants
should remain fully folded at 37uC in the stomach, hence resisting
pepsin degradation (and denaturation) to a higher extent than
wild-type VHHs, a statement supported by our in vitro pepsin
digestion experiments. In contrast to the mutants, 3 wild-type
VHHs, for example, have low Tonset values of 37.8uC (A5.1 and
A20.1) and 40.3uC (A26.8) which suggests they would partially
unfold in the stomach (pH > 2.0, 37uC), increasing their
proteolytic susceptibility. This indeed is the case in an in vitro
setting as A5.1 and A20.1, VHHs with Tonset temperatures
overlapping the physiological temperature, are completely pepsin
sensitive, and A26.8 with a Tonset slightly above the physiological
temperature, although somewhat better than the former two, is
barely resistant to pepsin (pepsin resistance: <3%). In the
corresponding pepsin resistant mutants, acquiring resistance
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observe a strong positive correlation between pepsin resistance and
Tonset (Fig. 8), and depending on the melting curve profile, Tonsets
may be better predictors of protein pepsin resistance than Tms.
Compared to other studies involving in vitro VHH proteolysis,
our mutant VHHs performed remarkably well, withstanding near
physiological concentrations of pepsin and chymotrypsin and
retaining functionality thereafter. Additionally, half of the mutants
were trypsin resistant and for those which were not, identification
and removal of their cleavage site(s) should be straightforward,
e.g., by MS analysis and site-directed mutagenesis. Balan et al [65]
note the human stomach contains pepsin concentrations ranging
from 500 mg/mL to 1 mg/mL, while Schmidt et al [66] found the
average pepsin concentration in the stomach of piglets to be
155 U/mL. Our pepsin digestion assays were performed at
100 mg/mL concentrations, which correspond to 46 U/mL. The
most stable VHH mutant produced by Harmsen et al [49] using a
DNA shuffling approach showed only 21% residual VHH
remaining after digestion with 100 mg/mL of pepsin. In contrast,
our most stable VHH (A4.2m) showed 74% residual VHH
remaining after digestion, while 4 others had residual pepsin
resistance values of 24% or higher. In addition, all 4 disulfide bond
mutant VHHs retained binding to TcdA after pepsin treatment,
confirming their resistance to the protease and retention of
functionality.
We also examined the toxin A neutralizing efficacy of our
disulfide bond mutant VHHs. Compared to the wild-type VHHs,
the mutants were 3–4 fold weaker with respect to toxin A
neutralization in cell-based assays, presumably a reflection in the
reduced affinities of 3 of 4 VHHs for the toxin. If a more thorough
analysis was performed on individual VHHs, it is possible that
clone A4.2m, which showed the same affinity as A4.2 for toxin A,
might be a more potent neutralizer due to its higher stability.
Under stringent conditions in vivo, the lower affinity mutants may
actually be more efficacious than the higher affinity wild-type
VHHs due to their greater stability, as shown elsewhere [50]. Also,
a number of methods are available to increase the affinity of the
disulfide-stabilized domains, allowing for the creation of superpo-
tent toxin A neutralizing antibodies capable of withstanding a wide
range of harsh conditions.
In conclusion, we have shown that the introduction of a second
disulfide bond into the hydrophobic core of a panel of llama VHHs
increased thermal stability and GI protease resistance; the
approach is both effective and general. The approach does not
come without some drawbacks, including, reduced affinity,
specificity, and expression yield. However, the mutants outper-
formed the wild-type VHHs under more stringent physiological
conditions, which outweighs the reductions in affinity, as noted
above. Whether the mutant VHHs are more efficacious than the
wild-type VHHs in vivo remains to be determined. Based on our
results and those of others, we suggest incorporating the non-
canonical disulfide bond between position 54 and 78 at the library
construction phase and not after the selection/screening phase to
avoid adverse side effects on affinity and specificity seen here and
in other studies. Other approaches, such as affinity maturation,
could be used to overcome losses in target affinity as a result of
disulfide bond incorporation. Our mutant VHHs are ideal building
blocks for oral therapeutic agents that must survive the harsh GI
tract, and provide promising alternatives to antibiotics. The oral
administration of therapeutic proteins is of interest to the
pharmaceutical and biotechnological industries [29,63,67,68].
Protein-based oral therapeutics have several conceived advantages
over systemic administration: convenience, patience compliance,
lower cost, pain-free administration, drug purity, flexibility in
production source (i.e., bacterial, plant, etc.), and fewer concerns
over immunogenicity. Despite the many advantages of orally
administering protein therapeutics, few successes have been
realized due to the destabilizing environment of the GI tract. Of
the major GI proteases, pepsin is considered the primary cause of
antibody degradation [29,35,49] and hence a major obstacle
facing orally delivered antibody therapeutics. Regarding the
mutant VHHs generated in this study, the therapeutic efficacy
can be further enhanced by improving their affinity (through
selection of affinity maturation display libraries) and by formula-
tion. The affinity maturation libraries could yield VHHs which are
hyper-stabilized (e.g., high GI protease resistance) in addition to
being of ultra-high affinity, if selection pressures (acid, proteases,
heat) are applied during the panning stage [43,45]. Indeed, the
correlation between VHH pepsin resistance and Tm suggests that
selection under heat should produce pepsin-resistant VHHs. Given
their stability profile, the mutants may be resistant to serum
degradation, making them efficacious systemic therapeutics if they
are coupled to a half-life extending molecule. Other applications
for our stabilized domains include: (i) use as delivery agents for
mucosal vaccines [69] or (ii) use as robust affinity purification
reagents resistant to acidic and heat elution steps. Furthermore,
the recent incorporation of these engineered disulfide bonds into
human VH sdAbs not only resulted in increased thermal stability,
but also markedly reduced VH aggregation [70], suggesting that
the introduced disulfide bond imparts a universal stabilizing effect
in all immunoglobulin variable domains.
Supporting Information
Figure S1 Alignment and comparison of wild-type and
mutant VHH amino acid sequences. Wild-type VHH
sequences are shown with a single disulfide bond between Cys
23
and Cys
104. A second disulfide bond was introduced through
mutation of Ala
54/Gly
54 and Ile
78 to Cys
54 (*) and Cys
78 in
framework region 2 (FR2) and FR3, respectively. Disulfide bonds
are shown as black lines. Residues colored in blue illustrate the
disulfide bond-linked peptides identified by nanoRPLC-ESI-MS
analysis on CNBr and trypsin digested mutant VHHs (Fig. 2).
Amino acid numbering and CDR designation is based on the
IMGT system (http://imgt.cines.fr/).
(TIF)
Figure S2 Far-UV CD analysis of VHHs at neutral and
acidic pH. CD scans (210 nm–260 nm) were performed at 25uC
on VHHs (50 mg/mL) equilibrated for 2 h in 10 mM sodium
phosphate buffer (pH 7.3) or 10 mM sodium phosphate buf-
fer+50 mM HCl (pH 2.0). The spectra represent the mean residue
ellipticity of 8 data accumulations collected from 2 independent
experiments. Raw data were smoothed using the Jasco software
and converted to mean residue ellipticity as described in Methods.
Red lines: wild-type VHH at pH 7.3; blue lines: mutant VHHa t
pH 7.3; green lines: wild-type VHH at pH 2.0; orange lines:
mutant VHH at pH 2.0.
(TIF)
Figure S3 Near-UV CD analysis of VHHs at neutral and
acidic pH. CD scans (250 nm–340 nm) were performed at 25uC
on VHHs (250 mg/mL) equilibrated for 2 h in 10 mM sodium
phosphate buffer (pH 7.3) or 10 mM sodium phosphate buf-
fer+50 mM HCl (pH 2.0). The spectra represent the mean residue
ellipticity from 8 data accumulations collected from 2 independent
experiments. Raw data were smoothed using the Jasco software
and converted to mean residue ellipticity as described in Methods.
Red lines: wild-type VHH at pH 7.3; blue lines: mutant VHHa t
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mutant VHH at pH 2.0.
(TIF)
Figure S4 VHH thermal unfolding curves. (A) Thermal
unfolding of wild-type and mutant VHHs (50 mg/mL) at pH 7.3
(10 mM sodium phosphate buffer) and pH 2.0 (10 mM sodium
phosphate buffer+50 mM HCl) were followed at 215 nm to
identify the thermal unfolding midpoint temperature (Tm). The Tm
was determined for each curve by Boltzmann non-linear curve
fitting analysis in GraphPad Prism. The goodness of curve fit (r
2)
ranged from 0.9901–0.9995. In the case of VHHs with few lower
baseline data points the Tm is a minimal estimate (see Table 3). Red
lines: wild-type VHH at pH 7.3; blue lines: mutant VHHa t
pH 7.3; green lines: wild-type VHH at pH 2.0; orange lines:
mutant VHH at pH 2.0. (B) Raw thermal unfolding data used to
generate the normalized curves in (A).
(TIF)
Figure S5 VHH resistance profiles against trypsin and
chymotrypsin. Wild-type (WT) and mutant (Mut) VHHs were
digested with 100 mg/mL of chymotrypsin or trypsin for 1 h at
37uC and separated by SDS-PAGE. Resistance values were
calculated as in Fig. 6.
(TIF)
Figure S6 Correlation between VHH protease resistance
and the number of theoretical proteolytic cleavage sites.
Linear regression between VHH protease resistance and the
number of theoretical cleavage sites within the whole VHH (‘‘Total
sites’’) or within the IMGT-defined CDR regions (‘‘CDR sites’’).
Wild-type and mutant VHH protease resistance values were
combined for each protease. The number of protease cleavage
sites was determined as in Table S3. Linear regression analysis was
used to analyze the correlation coefficient (r
2) and significantly
non-zero slope of the line (p) in each graph.
(TIF)
Table S1 Primers used in this study.
(PDF)
Table S2 Onset temperatures (Tonsets) of wild-type and
mutant VHHs.
(PDF)
Table S3 Theoretical number of protease cleavable
sites located within VHHs.
(PDF)
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